Chronic Visceral Leishmaniasis in a Patient with Advanced Human Immunodeficiency Virus Infection
DOI:
https://doi.org/10.24950/rspmi.574Keywords:
Leishmaniasis Visceral, HIV Infections, CoinfectionDownloads
References
Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HI- V-infection. Curr Opin Infect Dis. 2013; 26: 1-9.;
Ritmeijer K, ter Horst R, Cane S, Aderie EM et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis.2011; 53: e152-8.;
Desjeux P, Alvar J. Leishmania / HIV co-infections: Epidemiology in Euro- pe. Ann Trop Med Parasitol. 2003; 97: S3-15.;
Sindermann H, Engel KR, Fisher C, Bommer D et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis. 2004; 39:1520-3.;
McQuarrie S, Kasper K, Moffatt D, Marko D. Relapse of visceral leishma- niasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B. Can J Infect Dis Med Microbiol. 2015; 26: 325-9.;
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medicina Interna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
